Your browser is no longer supported. Please, upgrade your browser.
NRx Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.84 Insider Own1.40% Shs Outstand47.46M Perf Week-10.50%
Market Cap766.08M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float7.68M Perf Month34.17%
Income-2.30M PEG- EPS next Q- Inst Own2.60% Short Float1.85% Perf Quarter-55.96%
Sales- P/S- EPS this Y-596.10% Inst Trans432.88% Short Ratio0.04 Perf Half Y-74.45%
Book/sh0.45 P/B35.60 EPS next Y- ROA-37.00% Target Price- Perf Year49.58%
Cash/sh0.00 P/C- EPS next 5Y- ROE-88.80% 52W Range8.39 - 76.99 Perf YTD-34.34%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-79.19% Beta0.04
Dividend %- Quick Ratio0.10 Sales past 5Y- Gross Margin- 52W Low90.94% ATR2.97
Employees2 Current Ratio0.10 Sales Q/Q- Oper. Margin- RSI (14)52.21 Volatility16.19% 23.96%
OptionableYes Debt/Eq2.42 EPS Q/Q-446.10% Profit Margin- Rel Volume0.40 Prev Close16.20
ShortableNo LT Debt/Eq2.42 Earnings- Payout- Avg Volume3.95M Price16.02
Recom- SMA2021.02% SMA500.97% SMA200-34.80% Volume1,571,627 Change-1.11%
Aug-04-21 06:48AM  
Jul-27-21 11:34AM  
Jul-22-21 06:48AM  
Jul-19-21 06:48AM  
Jul-12-21 11:18AM  
Jul-06-21 09:20AM  
Jun-15-21 07:33AM  
Jun-09-21 02:50PM  
Jun-08-21 02:03PM  
Jun-07-21 01:45PM  
Jun-01-21 06:28AM  
May-27-21 06:48AM  
May-26-21 09:29AM  
NRx Pharmaceuticals, Inc. a clinical-stage, small molecule pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was incorporated in 2015 and is headquartered in Wilmington, Delaware.